30 results about "Organ dysfunction" patented technology

The invention discloses a sepsis patient organ function damage early warning judgment method based on machine learning, and the method comprises the steps: obtaining the multi-modal clinical data of a sepsis patient, including vital sign time sequence data, inspection data, treatment intervention data and static patient basic information; after data standardization processing, organ function associated features are extracted through a multi-scale feature fusion strategy, and an organ-level feature set is constructed; the method comprises the following steps of: obtaining a multi-organ collaborative early warning model, inputting the multi-organ collaborative early warning model into a pre-trained multi-organ collaborative early warning model, respectively constructing an inter-organ compensatory relation map by double branches of the model, quantifying organ injury risk contribution degree, and outputting a multi-organ functional injury risk matrix by combining with attention mechanism weighted fusion; and generating an early warning result based on the risk matrix and the organ specificity early warning threshold, including the injury risk level of each organ and the dominant risk key feature identifier, monitoring data update in real time, and dynamically adjusting the interval to update the early warning result. According to the invention, the limitation of traditional single-source data and single-organ early warning is broken through, and the early warning accuracy and real-time performance are improved.

Systems and methods for the detection of sepsis and treatment of patients. A sepsis detection system includes a first subsystem configured to detect the presence of an infection in a patient, a second subsystem configured to detect the presence of a dysregulated immune response in the patient, a third subsystem configured to detect organ dysfunction in the patient, a fourth subsystem configured to detect antibiotic resistance (ARB) of a pathogen in the patient, and a processing device. The first, second, third, and fourth subsystems and the processing device are communicatively coupled to each other via a network. The processing device is configured to determine the presence of sepsis in the patient based on the presence of infection, the presence of the dysregulated host response, and clinical data indicative of organ dysfunction in the patient.The subsystems utilize at least one polymerase chain reaction (PCR) procedure, Raman spectroscopy, clinical data, electronic health record (EHR) data, and antibiotic susceptibility testing (antibiogram).

The disclosed invention is a method for mapping glutathione deficiency and / or mitochondria dysfunction in disease states, utilizing glutathione and its precursors as imaging tracers in conjunction with medical imaging techniques, particularly magnetic resonance imaging. The innovation involves administering glutathione or glutathione-increasing interventions, such as oral liposomal reduced glutathione, to enhance imaging accuracy. The proposed methodology aims to identify and monitor regions of depleted reduced glutathione (GSH) in various organs and tissues. The maps generated through this process provide valuable biomarkers for toxic exposure, early biological effects, and health risks. The approach is versatile, offering applications in mental health, neurological disorders, inflammation, organ dysfunction, and personalized treatment and risk assessments.

This invention relates to the field of multi-organ dysfunction (MOD) early warning technology, specifically to an MOD early warning method for patients with severe burns. The method includes the following steps: acquiring heart rate, mean arterial pressure, respiratory rate, blood oxygen saturation, lactate concentration, and urine output per unit time; calculating the rate of lactate change at adjacent time points to form a sequence; comparing the rate of change across time intervals to obtain the difference in change; combining heart rate and blood oxygen saturation to calculate circulatory load; and counting the number of early warning triggers that meet risk conditions. In this invention, by calculating the rate of change of lactate concentration at adjacent time points and combining it with interval direction statistics, tissue metabolic changes show trend characteristics; the rate of change of urine output combined with mean arterial pressure forms a record of renal perfusion changes, providing a continuous characterization of perfusion status; heart rate and blood oxygen saturation are used to calculate circulatory load; multiple physiological signals are linked for judgment; and recurring abnormalities are expressed through the number of triggers. This improves the stability and predictability of MOD risk identification in critically burned patients.

The invention belongs to the field of biological medicines, and particularly discloses application of extracellular vesicles EVs carrying CD35 functional molecules in preparation of medicines for treating sepsis-related multi-organ injury, preferably, the EVs are derived from human podocytes or other cells or tool cells capable of naturally or engineered expressing CD35, and the EVs are administrated through caudal vein injection and can be used for preparing medicines for treating sepsis-related multi-organ injury. Normal saline is taken as a carrier, and the dosage of 1 * 10 < 10 > EVs each time is once every 12 hours and twice continuously. It is proved for the first time that EVs carries CD35 to inhibit circulation mononuclear cell complement activation (the EVs are combined with C3b to block downstream complement cascade reaction), migration of mononuclear cells to the kidney, the heart, the liver and the lung is reduced, and therefore multi-organ inflammation damage and cell apoptosis are relieved. In a cecum ligation perforation (CLP) sepsis model, it is proved that the medicine significantly improves the survival rate of mice, improves renal functions (reduces creatinine / urea nitrogen) and kidney pathological tissue damage, and meanwhile relieves pathological damage of multiple organs of the heart, the liver and the lung. The invention provides a new treatment strategy and drug candidate for sepsis-related multi-organ dysfunction.

The invention belongs to the technical field of biotechnology and medicine, and particularly relates to application of an Anapc11 gene / protein to screening of drugs for treating hyperuricemia-related multi-organ dysfunction. According to the invention, the Anapc11 gene is used as a molecular target or a drug action target, and is used for screening or preparing drugs for treating multi-organ dysfunction (including liver injury, testis dysfunction, intestinal barrier destruction and the like) caused by hyperuricemia. The invention provides a new application of the cell cycle promoting complex subunit E3 ubiquitin ligase Anapc11 gene, provides a new molecular target for treating hyperuricemia related multi-organ dysfunction, and breaks through the limitation that the existing uric acid reducing medicine is only limited to a metabolic link; a new direction and a good application prospect are provided for developing innovative medicines with organ protection effects.

The invention relates to the technical field of biological medicines, in particular to application of EGCG (epigallocatechin gallate) and a preparation thereof in inhibiting vibrio vulnificus or diseases caused by the vibrio vulnificus. It is found for the first time that EGCG can inhibit growth of vibrio vulnificus, destroy cell membranes of the vibrio vulnificus and inhibit formation of mycoderm, meanwhile, TLR4, MyD88 and / or NF-kappa B signal channels can be adjusted, host inflammatory response and organ dysfunction are relieved, and therefore EGCG can be used for preventing and / or treating vibrio vulnificus sepsis caused by the vibrio vulnificus; the blank of the existing treatment means in the aspect of anti-vibrio vulnificus and immune double-target intervention is filled, and important theoretical significance and application prospects are achieved.

The present invention provides an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce organ dysfunction or organ failure. In a preferred embodiment, the invention provides an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce renal dysfunction or renal failure or hepatic dysfunction or hepatic failure.

This invention provides the application of baicalin in the preparation of drugs antagonizing jellyfish toxin lethality, belonging to the field of pharmaceutical technology. Experiments have verified that baicalin can alleviate multi-organ dysfunction caused by jellyfish stings. Cell experiments show that baicalin can significantly increase the proliferation rate of RAW 264.7 cells and antagonize jellyfish toxin-induced apoptosis; mouse experiments show that baicalin can significantly improve mouse survival rate and alleviate the damage to the heart, liver, and kidneys caused by jellyfish toxin.

The present invention relates to metal nanoparticles and a plasmonic biosensor including the same. According to the present invention, it is possible to provide novel metal nanoparticles having significantly improved sensitivity to light, and further, it is possible to provide a plasmonic biosensor capable of detecting a trace amount of a biomarker present in a biological sample with high precision through the metal nanoparticles. In addition, the plasmonic biosensor is capable of detecting a sepsis biomarker with high sensitivity and specificity, and thus may be usefully used in various clinical applications such as sepsis diagnosis, identification of the type of organ dysfunction, prediction of sepsis severity, and post-treatment.

Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolysis. VOC is the clinically painful form of vaso-occlusion, that is due to the aggregation of red blood cells in the capillaries and venules. Such event is promoted or aggravated by adhesion of polymorphonuclear neutrophils (PMNs) to red blood cells and the endothelium leading to tissue ischemia, inflammation and imperfect repair. Repeated vaso-occlusion and PMNs interactions with the vascular endothelium are thought to promote microvascular injuries in SCD patients. The inventors tested the effect of pharmacological inhibition of TREM-1 with LR12 peptide in two experimental vaso-occlusive crisis models. Additional validation of TREM-1 involvement in vaso-occlusion was verified using mice with sickle cell disease and Trem-1 gene deficiency. In particular, the inventors showed that TREM-1 inhibition is particular suitable for limiting the severity of vaso-occlusions. The results obtained by the inventors also suggest that plasmatic concentration of sTREM-1 could be a reliable biomarker for predicting vaso-occlusions and / or SCD-associated organ dysfunction and end-organ damage.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute lung injury and a preparation method and application thereof. The traditional Chinese medicine composition for treating the acute lung injury is prepared from the following raw materials in parts by weight: 10 to 15 parts of cortex moutan, 15 to 25 parts of radix paeoniae rubra, 25 to 35 parts of radix rehmanniae recen, 10 to 20 parts of semen persicae, 10 to 20 parts of fructus aurantii immaturus, 10 to 15 parts of radix curcumae, 10 to 15 parts of rhizoma acori graminei, 15 to 25 parts of fructus trichosanthis, 10 to 20 parts of fructus forsythiae, 10 to 20 parts of rhizoma polygoni cuspidati, 15 to 25 parts of semen lepidii and 25 to 35 parts of radix astragali seu hedysari. The traditional Chinese medicine composition has the beneficial effects that the traditional Chinese medicine composition for treating the acute lung injury can play a role in the aspects of improving the immune state, improving circulation and the like by influencing the release of inflammatory factors; the traditional Chinese medicine composition can improve the treatment effective rate and off-line success rate of acute lung injury patients, shorten the mechanical ventilation time, improve the oxygenation index of the patients, reduce the expression of proinflammatory factors IL-6, regulate the immune balance of Th1 / Th2 and Th17 / Treg, improve hemagglutination and relieve the disease severity and multi-organ dysfunction of the patients.

The invention discloses a traditional Chinese medicine composition for preventing and treating sepsis microcirculation and blood coagulation dysfunction. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-40 parts of ginseng, 5-15 parts of rheum officinale, 20-40 parts of sargentgloryvine stem, 20-40 parts of dandelion, 20-40 parts of radix aconiti carmichaeli and 2-8 parts of leech. The traditional Chinese medicine composition has the effects of supporting the healthy energy, clearing away heat and toxic materials and promoting blood circulation to remove blood stasis, clinical tests show that the traditional Chinese medicine composition can remarkably improve microcirculation disturbance and blood coagulation dysfunction of a sepsis patient, reduce the 28-day full-cause case fatality rate of the patient, improve multi-organ dysfunction and relieve inflammatory response for the yang-deficiency and toxin-stasis type sepsis patient, and has good safety. In addition, the invention further discloses a preparation method and application of the traditional Chinese medicine composition.

The present application belongs to the field of biotechnology and medical technology, and particularly relates to Anapc11 gene / protein for screening drugs for treating hyperuricemia related multi-organ dysfunction. The present application uses Anapc11 gene as a molecular target or a drug action target for screening or preparing drugs for treating multi-organ dysfunction caused by hyperuricemia (including liver injury, testicular dysfunction and intestinal barrier damage). The present application provides a new use of cell cycle promoting complex subunit E3 ubiquitin ligase Anapc11 gene, provides a new molecular target for treating hyperuricemia related multi-organ dysfunction, breaks the limitation of existing uric acid lowering drugs only in the metabolic link, and provides a new direction and good application prospect for developing innovative drugs with organ protection effect.

A system and method is disclosed for measuring muscle reflexes (e.g., a bulbocavernosus reflex) as a tool for identifying / diagnosing dysfunctions (e.g., spinal cord abnormalities, bladder voiding dysfunction, and sexual organ dysfunction) non-invasively by using mechanical stimulation. The system and method includes a probe having a predetermined patient contacting portion, wherein when the contacting portion is moved into contact with a particular area of the patient (e.g., the patient's genitals), the contact induces a muscle reflex. The probe detects the pressure resulting from the contacting portion being abruptly and forcibly brought into contact with the particular area. Such detection is used to electronically initiate capture of electrical responses from a plurality of electrodes placed on the patient's skin in proximity to the particular area. Such electrical responses are processed to determine characteristics of the patient's reflexes of one or more muscles adjacent to thh: \e electrodes.

This invention belongs to the field of smart healthcare and digital health technology, providing a method and platform for intelligent monitoring and early warning of health risks for people with chronic diseases. The method includes: collecting physiological indicators, lifestyle habits, and traditional Chinese medicine constitution identification information, and fusing them to generate multi-dimensional time-series data on chronic disease characteristics; constructing and dynamically updating a personal dynamic health model; establishing a three-tiered progressive early warning mechanism of L1-level trend deviation, L2-level organ dysfunction, and L3-level complication risk, clarifying the triggering conditions for each level of early warning; based on the early warning level, calling upon a knowledge base of traditional Chinese and Western medicine intervention rules to generate and push personalized intervention plans; collecting feedback data to optimize the model and evaluate the intervention effect. The platform includes a smart terminal layer, a platform service layer, a model knowledge base, and an application interaction layer, adopting an edge-cloud collaborative architecture to improve monitoring real-time performance. This invention, through multi-dimensional data fusion and hierarchical early warning, can achieve early identification and accurate early warning of chronic disease risks.

The invention discloses an intelligent early warning system for cardiac intensive care, and the system comprises a treatment input module which is used for receiving the input parameters of a cardiac treatment drug and basic physical sign data of a patient; the data real-time acquisition module is used for acquiring ECG data, kidney marker data and respiratory function data of a patient; the exception handling module is configured to output a causal effect estimated value and an exception probability value through a pre-trained DML model, and output predicted concentration of a preset marker and predicted data of preset function data through a pre-trained NODE model; and the closed-loop control module is used for updating the pre-trained DML model and the pre-trained NODE model. Therefore, on one hand, heart treatment drug-related and non-drug-related sexual organ dysfunction can be accurately distinguished, clinical misjudgment is avoided, on the other hand, continuous time trajectory prediction of kidney and respiratory function indexes can be realized, and potential abnormality can be warned in advance.

The invention relates to the technical field of biological medicine, and particularly discloses application of Chinese yam vesicles in preparation of a medicine for preventing and treating sepsis. The Chinese yam vesicles are extracted from Chinese yam through a gradient ultrasonic centrifugation method; according to the scheme, the cognitive limitation that only the Chinese yam vesicles are used for bone metabolism related diseases in the prior art is broken through, and the Chinese yam vesicles are creatively applied to treatment of sepsis characterized by systemic inflammatory response and multi-organ dysfunction for the first time; moreover, experiments prove that the application can be used for remarkably improving the survival rate of sepsis model mice, effectively relieving pathological injuries of multiple organs such as liver, kidney and lung caused by sepsis, remarkably inhibiting the expression of key inflammatory factors TNF-alpha, IL-6 and IL-1beta in serum, and inhibiting the expression of inflammatory factors such as inflammatory factors TNF-alpha, IL-6 and IL-1beta in serum. Therefore, a definite intervention effect is generated on core pathological links (cytokine storm and organ injury) of sepsis; the scheme of the invention provides a brand-new candidate drug and treatment strategy with natural source advantages for solving the problem of clinical treatment of sepsis.

Methods of preventing and / or treating ischemia, organ dysfunction and / or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction / failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

The application discloses a sepsis organ dysfunction early warning method based on sparse data incremental coding, comprising the following steps: obtaining event sequence data and non-event sequence data of a target object, wherein the event sequence data comprises at least one of clinical diagnosis data, treatment record data and laboratory history detection data, and the non-event sequence data comprises at least past medical history data and target sign data; performing incremental coding on the event sequence data to obtain a sparse mode of the event sequence data; processing the sparse mode, the event sequence data and the non-event sequence data according to a pre-constructed early warning model to obtain a sepsis risk index of the target object; and outputting target early warning information in the case that the sepsis risk index meets preset early warning conditions.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a heat-purging stagnation-removing traditional Chinese medicine compound preparation and a preparation method and application thereof. The traditional Chinese medicine compound preparation for purging heat and removing stagnation is prepared from the following raw materials in parts by weight: 10-60 parts of radix bupleuri, 10-30 parts of radix scutellariae, 10-30 parts of radix paeoniae rubra, 10-30 parts of rhizoma pinelliae preparata, 10-40 parts of fresh ginger, 10-40 parts of fructus aurantii, 10-40 parts of cortex mori radicis, 10-30 parts of peach kernels, 10-30 parts of liquorice, 1-15 parts of cassia twig, 10-30 parts of fructus forsythiae, 1-15 parts of rhizoma cimicifugae and 8-30 parts of honeysuckle. The traditional Chinese medicine compound preparation for purging heat and removing stagnation is a self-formulated formula, takes bowel purging, heat purging, blood circulation promoting and blood stasis removing as main treatment methods, improves clinical symptoms of patients suffering from systemic inflammatory reaction, reduces the incidence rate of multi-organ dysfunction, and improves the living quality and prognosis of the patients.

The invention discloses an application of magnesium salvianolic acid B (MLB) in preparation of a medicine for preventing or treating sepsis and related multi-organ dysfunction of the sepsis, and particularly discloses an application of magnesium salvianolic acid B (MLB) in preparation of a medicine for preventing or treating the sepsis and the related multi-organ dysfunction of the sepsis and the related multi-organ dysfunction of the sepsis. Experiments prove that in a sepsis animal model, the MLB can significantly improve the survival rate, relieve multi-organ injury, improve hematological abnormality and organ functions, and relieve iron-dependent injury by stabilizing an antioxidant system. And the MLB is natural in source and high in safety, and has a potential application prospect as a candidate drug for preventing and treating sepsis. The invention provides an effective technical means for preventing or treating sepsis and related multi-organ dysfunction thereof.

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the disclosure relates to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

The invention relates to an application of a group of furocoumarin compounds in preparation of a medicine for inhibiting diseases caused by cell death. The furocoumarin compounds are white angelica, white angelica brain, alloimperatorin, imperatorin, hydrated oxidized imperatorin or decuricin. The invention also provides application of the furocoumarin compound in preparation of an experimental reagent for inhibiting diseases caused by cell death. Experiments show that imperatorin and hydrated oxidized imperatorin can significantly improve the survival rate of influenza lethal model mice. The hydrated oxypeucedanin can significantly reduce the fatality rate of cytokine storm syndrome model mice. The invention illustrates that the furocoumarin compound inhibits cell death, delays or blocks the occurrence of cytokine storm, further reduces the development of acute lung injury or multi-organ function failure, and has considerable clinical application prospects.

Embodiments relate to a method of treating a disease or condition in a subject in need thereof, the method comprising: administering a therapeutic effective amount of a pharmaceutical composition comprising mesenchymal cells and exosomes to the subject; wherein the mesenchymal cells and exosomes are in a ratio of about 1: 2500 to 1: 250000; wherein the mesenchymal cells have a stemness quality more than 90% and viability more than 95%, and the exosomes are free of a cellular contaminant as detected by immunoblotting technique, wherein the cellular contaminant comprises calnexin, and treating said disease or condition.

The present application relates to the use of plasma osteocalcin as a biomarker in the preparation of a diagnostic and / or prognostic product for sepsis in children. The prognostic product uses the measurement of osteocalcin levels on the first day of admission of a child with sepsis to assess the degree of organ dysfunction and the need for organ support in patients with sepsis. The present application discloses the potential of osteocalcin as a modulator of the immune inflammatory response in sepsis and that its level changes can be used as a predictive marker of the diagnosis and clinical outcome of sepsis. This finding provides a new biomarker for the early diagnosis, prognosis evaluation and treatment of sepsis and an important basis for clinical management.

The present disclosure provides the use of sodium octanoate in preparation of a medicine for improving the efficacy of cardiopulmonary resuscitation and post-resuscitation multiple organ dysfunction, and relates to the technical field of pharmaceutical preparation. The above medicine for improving the efficacy of cardiopulmonary resuscitation and post-resuscitation multiple organ dysfunction comprises the administration of a pharmaceutically effective dose of sodium octanoate. By administering a pharmaceutically effective dose of sodium octanoate that is used for promoting fatty acid oxidation energy supply during systemic ischemia-reperfusion injury caused by cardiac arrest and resuscitation, this medicine can further effectively improve the efficacy of cardiopulmonary resuscitation and post-resuscitation multiple organ dysfunction.

The present invention relates to the technical field of biomedicine, and specifically provides an empowered mesenchymal stem cell, an empowered mesenchymal stem cell composition, and use thereof in the preparation of a drug for treating organ dysfunction. The empowered mesenchymal stem cell is obtained by treating human mesenchymal stem cells with ingenol HEP14. The empowered mesenchymal stem cell composition comprises the empowered mesenchymal stem cell and an HEP14 / PLGA microsphere having a high HEP14 loading capacity and a long-acting HEP14 sustained release prepared by using poly(lactic-co-glycolic acid) (PLGA) as a carrier. The empowered mesenchymal stem cell has the effects of enhancing the viability and stemness of mesenchymal stem cells, resisting tissue fibrosis, promoting tissue angiogenesis, and promoting tissue regeneration and functional recovery. The combined use of the empowered mesenchymal stem cell and the HEP14 / PLGA microsphere enhances the effects of retention and transdifferentiation of the empowered mesenchymal stem cell in tissues, thereby further enhancing the function of the empowered mesenchymal stem cell and the use thereof in the field of regenerative medicine.

The application belongs to the technical field of biomedicine, and specifically discloses a kind of enabled mesenchymal stem cells, enabled mesenchymal stem cell composition and its application in preparation treatment organ dysfunction drug, and the enabled mesenchymal stem cells are obtained by treating human mesenchymal stem cells with a kind of halogenated salicylic alcohol HEP14, and the enabled mesenchymal stem cell composition includes the enabled mesenchymal stem cells and HEP14 / PLGA microspheres with high HEP14 load and long-acting HEP14 sustained release prepared by using polylactic acid-hydroxyacetic acid copolymer (PLGA) as a carrier.The enabled mesenchymal stem cells of the application have the effects of strengthening mesenchymal stem cell survival viability and stemness, resisting tissue fibrosis, promoting tissue angiogenesis, promoting tissue regeneration and functional recovery;the combined application of the enabled mesenchymal stem cells and HEP14 / PLGA microspheres strengthens the retention and transdifferentiation of the enabled mesenchymal stem cells in the tissue, so the function of the enabled mesenchymal stem cells and the application in the field of regenerative medicine are further strengthened.

The invention belongs to the technical field of animal model construction, and discloses a sepsis model construction method, which comprises: preparing a bacterial liquid, carrying out culture amplification on Escherichia coli, carrying out centrifugal collection, washing with a sterile PBS buffer solution, and re-suspending to obtain the bacterial liquid; constructing a model, performing intraperitoneal injection of the bacterial liquid into piglet bodies, and performing intraperitoneal injection of an isopyknic sterile PBS buffer solution into a control group; and feeding: feeding the piglets subjected to intraperitoneal injection for 48 hours to obtain the sepsis model. The invention provides the method for constructing the sepsis model, and the model constructed by the method is simple to operate, stable in effect and good in repeatability, and can comprehensively simulate the inflammatory response of human sepsis, multi-organ dysfunction, intestinal injury and other core pathological characteristics. And a standardized tool with high clinical prediction value is provided for pathogenesis research and treatment evaluation of sepsis.